#161896

EN-1078D

Cat. #161896

EN-1078D

Cat. #: 161896

Organism: Human

Tissue: Ovary

Disease: Cancer

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Dery et al. 2007. Reproductive Biology and Endocrinology. 25,5:(38). PMID 17894888

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: EN-1078D
  • Organism: Human
  • Tissue: Ovary
  • Donor: Donor was 52 and menopaused since two years at time of diagnosis. Patient had poorly differentiated stage IIIC endometrial adenocarcinoma with ovarian and ganglionic metastasis. Patient was initially treated with megestrol acetate associated with local radiotherapy and endocervical curietherapy.
  • Disease: Cancer
  • Morphology: Small polygonal cells organized in pavement-like arrangement
  • Growth properties: Mixed
  • Crispr: No
  • Description: Endometrial carcinoma cell line originiating from simple epithelial cells. Positive for both estrogen receptor isoforms and progesterone receptor B, presents mutations in PTEN and K-Ras genes, one tumor suppressor and one oncogene frequently mutated in endometrial cancers. Cell line expresses high levels of MMP-2 , no MMP-9 and weak expression of TIMP-2. Cells have weak levels of phosphorylated Akt adn sow sensitivity to drugs commonly used in chemotherapy. Very aggressive cell line with high invasiveness in vitro Useful for studying mechanisms involved in the invasion of endometrial cancer cells and their regulation by sex steroids.
  • Production details: Tumor was minced with scisors into OSE without FBS. Enzymatic dissociation was done and the cellular fraction was diluted 1:5 in OSE media with 10% FBS in 37C in 5%CO2 for 24-28 hours. After cells were able to adhere, they were washed with PBS and passaged with OSE + 10% FBS until cell line was established. Afterwards, cells were grown and maintained in DMEM-F12 with HEPES (4-(4-hydroxyethyl)-1-piperazineethanesulfonic acid) adn teh medium was supplemented with 10&v/v bovine growth serum (BGS) and 50ug/ml gentamycin.
  • Biosafety level: 1

Handling

  • Format: Frozen
  • Growth medium: Grown and maintained in DMEM-F12 with HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) supplemented with 10% v/v bovine growth serum (BGS) and 50 ug/ml gentamycin. For experimentation without steroid hormones, cell line cultured 2 weeks minimum in phenol-free DMEM-F12 supplemented with 10% v/v dextran-charcol stripped FBS and 50ug/ml gentamycin.
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen
  • Characterisation tests: Protein extraction and Western analysis, semi-quantitative RT-PCR analysis, MTT proliferation assays, cytogenetic analysis, invasion assay, in vivo growth assay, and in vitro growth assay
  • Str profiling: TH01: 6,9 / D21S11: 29,30 / D5S818: 9,13 / D13S317: 8,14 / D7S820: 8,14 / D16S539: 12 / CSF1PO: 10,11 / vWA: 17,18 / TPOX: 8,11 / AMEL: X

References

  • Fabi, et al. 2021. Mol Oncol. 15(8):2106-2119. PMID: 33338300
  • Aslan, et al. 2018. BMC Cancer. 9,18(1):168. PMID: 29426295
  • Coyne, et al. 2013. J Clin Exp Oncol. 2(2):1000109. PMID: 26251840
  • Dery et al. 2007. Reproductive Biology and Endocrinology. 25,5:(38). PMID 17894888